SPIRIT PRIME JAPAN (SV JAPAN)
Phase of Trial: Phase III
Latest Information Update: 18 Aug 2015
At a glance
- Drugs Everolimus (Primary)
- Indications Angina pectoris; Coronary artery disease; Coronary artery restenosis; Ischaemia; Myocardial ischaemia; Unstable angina pectoris
- Focus Therapeutic Use
- Acronyms SV JAPAN
- Sponsors Abbott Laboratories
- 10 Jun 2017 Biomarkers information updated
- 12 Aug 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 29 Jun 2011 Planned end date changed from 1 Jun 2016 to 1 Aug 2016 as reported by ClinicalTrials.gov.